Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $117,855 | 59 | 100.0% |
| Food and Beverage | $24.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $111,766 | 55 | $0 (2024) |
| Shire North American Group Inc | $6,088 | 4 | $0 (2019) |
| Supernus Pharmaceuticals, Inc. | $24.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,504 | 13 | Takeda Pharmaceuticals U.S.A., Inc. ($26,480) |
| 2023 | $16,853 | 8 | Takeda Pharmaceuticals U.S.A., Inc. ($16,853) |
| 2022 | $24,080 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($24,080) |
| 2021 | $21,473 | 11 | Takeda Pharmaceuticals U.S.A., Inc. ($21,473) |
| 2020 | $22,880 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($22,880) |
| 2019 | $6,088 | 4 | Shire North American Group Inc ($6,088) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 08/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 07/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 05/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 04/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 03/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 02/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 01/20/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 01/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 12/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 11/10/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 10/09/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 09/13/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,206.66 | General |
| 07/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
| 06/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
| 04/07/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
| 02/08/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
| 12/07/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
| 11/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
| 10/05/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
| 09/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,006.66 | General |
About Brian Lecleir
Brian Lecleir is a Pediatrics healthcare provider based in Grand Rapids, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/26/2012. The National Provider Identifier (NPI) number assigned to this provider is 1417211301.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Brian Lecleir has received a total of $117,879 in payments from pharmaceutical and medical device companies, with $26,504 received in 2024. These payments were reported across 60 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($117,855).
Practice Information
- Specialty Pediatrics
- Location Grand Rapids, MI
- Active Since 06/26/2012
- Last Updated 06/26/2012
- Taxonomy Code 208000000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417211301
Products in Payments
- Qelbree (Drug) $24.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Grand Rapids
Dr. Theodore Kelbel, M.d, M.D
Pediatrics — Payments: $525,946
Dr. Randall Leja, D.o, D.O
Pediatrics — Payments: $230,024
Vilnis Meiers, Md, MD
Pediatrics — Payments: $75,845
Allison Bannick, Np, NP
Pediatrics — Payments: $52,209
Dr. Alejandra Escobar Vasco, Md, MD
Pediatrics — Payments: $11,055
Lisa Lowery, Md, MD
Pediatrics — Payments: $10,794